Gee Julianne, Weinbaum Cindy, Sukumaran Lakshmi, Markowitz Lauri E
a Division of Healthcare and Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA.
b Division of Viral Diseases, National Center Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta , GA , USA.
Hum Vaccin Immunother. 2016 Jun 2;12(6):1406-17. doi: 10.1080/21645515.2016.1168952. Epub 2016 Mar 30.
Quadrivalent human papillomavirus (4vHPV) vaccine was licensed for use in the United States in 2006 and through 2015 was the predominate HPV vaccine used. With the exception of syncope, a known preventable adverse event after any injected vaccination, both pre-licensure and post-licensure 4vHPV safety data have been reassuring with no confirmed safety signals identified. Nine-valent HPV vaccine (9vHPV) was licensed in 2014. This review includes post-licensure 4vHPV safety findings published to date that have informed the US vaccination program; these data will inform US safety monitoring and evaluation for 9vHPV.
四价人乳头瘤病毒（4vHPV）疫苗于2006年在美国获得许可使用，在2015年之前一直是主要使用的HPV疫苗。除晕厥这一任何注射疫苗后已知的可预防不良事件外，4vHPV疫苗在获得许可前和获得许可后的安全性数据都令人放心，未发现确认的安全信号。九价HPV疫苗（9vHPV）于2014年获得许可。本综述包括迄今为止已发表的4vHPV疫苗获得许可后的安全性研究结果，这些结果为美国的疫苗接种计划提供了参考；这些数据将为美国对9vHPV疫苗的安全性监测和评估提供参考。
